Loading…

EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma

The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enh...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2020-12, Vol.25 (12), p.1067-1074
Main Authors: Michaleas, Sotirios, Penninga, Elisabeth, Hovgaard, Doris, Dalseg, Anne‐Marie, Rosso, Aldana, Sarac, Sinan B., Jimenez, Jorge Camarero, Fernández, Lucia López‐Anglada, Fernández, Carolina Prieto, Mangas‐SanJuan, Victor, Garcia, Isabel, Payares‐Herrera, Concepcion, Sancho‐López, Aranzazu, Enzmann, Harald, Castro Lopes Silva, Marcia Sofia Sanches, Duarte, Sílvia, Pignatti, Francesco
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93
cites cdi_FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93
container_end_page 1074
container_issue 12
container_start_page 1067
container_title The oncologist (Dayton, Ohio)
container_volume 25
creator Michaleas, Sotirios
Penninga, Elisabeth
Hovgaard, Doris
Dalseg, Anne‐Marie
Rosso, Aldana
Sarac, Sinan B.
Jimenez, Jorge Camarero
Fernández, Lucia López‐Anglada
Fernández, Carolina Prieto
Mangas‐SanJuan, Victor
Garcia, Isabel
Payares‐Herrera, Concepcion
Sancho‐López, Aranzazu
Enzmann, Harald
Castro Lopes Silva, Marcia Sofia Sanches
Duarte, Sílvia
Pignatti, Francesco
description The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enhanced efficacy and tolerability in both transplant‐ineligible (MMY3008 and MMY3007) and transplant‐eligible (MMY3006) patients, without compromising transplant ability. Trial MMY3008 showed an improvement in progression‐free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone; the median PFS had not been reached in the daratumumab arm and was 31.9 months in the control arm (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.43–0.73; p < .0001). Trial MMY3007 showed an improvement in PFS when daratumumab was added to bortezomib, melphalan, and prednisone compared with bortezomib, melphalan, and prednisone; PFS had not been reached in the daratumumab arm and was 18.1 months in the control arm (HR, 0.5; 95% CI, 0.38–0.65; p < .0001). In trial MMY3006, daratumumab added to bortezomib, thalidomide, and dexamethasone was compared with bortezomib, thalidomide, and dexamethasone as induction and consolidation treatment prior to autologous stem cell transplant. The stringent complete response rate at day 100 after transplant in the daratumumab group was 29% compared with 20% in the control group (odds ratio, 1.60; 1.21–2.12 95% CI; p = .0010). Overall adverse events were manageable, with an increased rate of neutropenia and infections in the daratumumab arms. Regulatory assessment of efficacy and safety results from trials MMY3006, MMY3007, and MMY3008 confirmed a positive benefit‐risk ratio leading to an approval of the extensions of indication. Implications for Practice A set of extensions of indication was recently approved for daratumumab (Darzalex) in the setting of newly diagnosed multiple myeloma in combination with established regimens. Results of the MMY3006, MMY3007, and MMY3008 trials have shown enhanced efficacy and a favorable side effect profile of several daratumumab‐based combinations in patients both ineligible and eligible for transplant, without compromising transplant ability. The combinations of daratumumab with either lenalidomide and low‐dose dexamethasone or bortezomib, melphalan, and prednisone were approved for transplant‐ineligible patients. The combination of daratumuma
doi_str_mv 10.1002/onco.13554
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7938407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2449182429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqVw4QcgHwtSyvgjm_iCtNqWD6nbRahI3KxJPOkaOfE2drosv54sWyq4cJoZ-9EzI71Z9pLDGQcQb0PfhDMui0I9yo55oXSuNHx7PPVQybzkhT7KnsX4HWBqpXiaHUkJYlYCHGf9xXLOvtCdoy0LLTvHAdPYjR3W7HQafqKnH69ZGwaW1sSuB8LUUZ_27NyOPrHPmNz0ENkVbf2OnTu86UMky7YurdlyQtzGE1vuyIcOn2dPWvSRXtzXk-zr-4vrxcf8cvXh02J-mTdKgMoboJKwQIVcNjgDri02TalBq0IRl7Yha8FqrLAGIYoZlhaIV4Sztra1lifZu4N3M9YdTXifBvRmM7gOh50J6My_P71bm5twZ0otKwXlJDi9FwzhdqSYTOdiQ95jT2GMRiileSWU2O96c0CbIcQ4UPuwhoPZB2T2AZnfAU3wq78Pe0D_JDIB_ABsnafdf1RmdbVYHaS_ADDsngA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2449182429</pqid></control><display><type>article</type><title>EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma</title><source>Open Access: Oxford University Press Open Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Michaleas, Sotirios ; Penninga, Elisabeth ; Hovgaard, Doris ; Dalseg, Anne‐Marie ; Rosso, Aldana ; Sarac, Sinan B. ; Jimenez, Jorge Camarero ; Fernández, Lucia López‐Anglada ; Fernández, Carolina Prieto ; Mangas‐SanJuan, Victor ; Garcia, Isabel ; Payares‐Herrera, Concepcion ; Sancho‐López, Aranzazu ; Enzmann, Harald ; Castro Lopes Silva, Marcia Sofia Sanches ; Duarte, Sílvia ; Pignatti, Francesco</creator><creatorcontrib>Michaleas, Sotirios ; Penninga, Elisabeth ; Hovgaard, Doris ; Dalseg, Anne‐Marie ; Rosso, Aldana ; Sarac, Sinan B. ; Jimenez, Jorge Camarero ; Fernández, Lucia López‐Anglada ; Fernández, Carolina Prieto ; Mangas‐SanJuan, Victor ; Garcia, Isabel ; Payares‐Herrera, Concepcion ; Sancho‐López, Aranzazu ; Enzmann, Harald ; Castro Lopes Silva, Marcia Sofia Sanches ; Duarte, Sílvia ; Pignatti, Francesco</creatorcontrib><description>The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enhanced efficacy and tolerability in both transplant‐ineligible (MMY3008 and MMY3007) and transplant‐eligible (MMY3006) patients, without compromising transplant ability. Trial MMY3008 showed an improvement in progression‐free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone; the median PFS had not been reached in the daratumumab arm and was 31.9 months in the control arm (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.43–0.73; p &lt; .0001). Trial MMY3007 showed an improvement in PFS when daratumumab was added to bortezomib, melphalan, and prednisone compared with bortezomib, melphalan, and prednisone; PFS had not been reached in the daratumumab arm and was 18.1 months in the control arm (HR, 0.5; 95% CI, 0.38–0.65; p &lt; .0001). In trial MMY3006, daratumumab added to bortezomib, thalidomide, and dexamethasone was compared with bortezomib, thalidomide, and dexamethasone as induction and consolidation treatment prior to autologous stem cell transplant. The stringent complete response rate at day 100 after transplant in the daratumumab group was 29% compared with 20% in the control group (odds ratio, 1.60; 1.21–2.12 95% CI; p = .0010). Overall adverse events were manageable, with an increased rate of neutropenia and infections in the daratumumab arms. Regulatory assessment of efficacy and safety results from trials MMY3006, MMY3007, and MMY3008 confirmed a positive benefit‐risk ratio leading to an approval of the extensions of indication. Implications for Practice A set of extensions of indication was recently approved for daratumumab (Darzalex) in the setting of newly diagnosed multiple myeloma in combination with established regimens. Results of the MMY3006, MMY3007, and MMY3008 trials have shown enhanced efficacy and a favorable side effect profile of several daratumumab‐based combinations in patients both ineligible and eligible for transplant, without compromising transplant ability. The combinations of daratumumab with either lenalidomide and low‐dose dexamethasone or bortezomib, melphalan, and prednisone were approved for transplant‐ineligible patients. The combination of daratumumab with bortezomib, thalidomide, and dexamethasone was approved for transplant‐eligible patients. These combinations are expected to improve the survival outlook for patients with multiple myeloma, without an unacceptable risk of increase in adverse events, and updated information on progression‐free survival and overall survival is expected from the above trials. This report outlines the regulatory steps taken for the approval of extensions of indication of daratumumab for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The pivotal clinical data submitted and EMA review of the benefit‐risk assessment are summarized.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1002/onco.13554</identifier><identifier>PMID: 33026700</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Daratumumab ; European Medicines Agency ; Newly diagnosed multiple myeloma ; Regulatory Issues: EMA</subject><ispartof>The oncologist (Dayton, Ohio), 2020-12, Vol.25 (12), p.1067-1074</ispartof><rights>AlphaMed Press 2020</rights><rights>AlphaMed Press 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93</citedby><cites>FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93</cites><orcidid>0000-0002-8926-2749</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938407/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938407/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33026700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michaleas, Sotirios</creatorcontrib><creatorcontrib>Penninga, Elisabeth</creatorcontrib><creatorcontrib>Hovgaard, Doris</creatorcontrib><creatorcontrib>Dalseg, Anne‐Marie</creatorcontrib><creatorcontrib>Rosso, Aldana</creatorcontrib><creatorcontrib>Sarac, Sinan B.</creatorcontrib><creatorcontrib>Jimenez, Jorge Camarero</creatorcontrib><creatorcontrib>Fernández, Lucia López‐Anglada</creatorcontrib><creatorcontrib>Fernández, Carolina Prieto</creatorcontrib><creatorcontrib>Mangas‐SanJuan, Victor</creatorcontrib><creatorcontrib>Garcia, Isabel</creatorcontrib><creatorcontrib>Payares‐Herrera, Concepcion</creatorcontrib><creatorcontrib>Sancho‐López, Aranzazu</creatorcontrib><creatorcontrib>Enzmann, Harald</creatorcontrib><creatorcontrib>Castro Lopes Silva, Marcia Sofia Sanches</creatorcontrib><creatorcontrib>Duarte, Sílvia</creatorcontrib><creatorcontrib>Pignatti, Francesco</creatorcontrib><title>EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enhanced efficacy and tolerability in both transplant‐ineligible (MMY3008 and MMY3007) and transplant‐eligible (MMY3006) patients, without compromising transplant ability. Trial MMY3008 showed an improvement in progression‐free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone; the median PFS had not been reached in the daratumumab arm and was 31.9 months in the control arm (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.43–0.73; p &lt; .0001). Trial MMY3007 showed an improvement in PFS when daratumumab was added to bortezomib, melphalan, and prednisone compared with bortezomib, melphalan, and prednisone; PFS had not been reached in the daratumumab arm and was 18.1 months in the control arm (HR, 0.5; 95% CI, 0.38–0.65; p &lt; .0001). In trial MMY3006, daratumumab added to bortezomib, thalidomide, and dexamethasone was compared with bortezomib, thalidomide, and dexamethasone as induction and consolidation treatment prior to autologous stem cell transplant. The stringent complete response rate at day 100 after transplant in the daratumumab group was 29% compared with 20% in the control group (odds ratio, 1.60; 1.21–2.12 95% CI; p = .0010). Overall adverse events were manageable, with an increased rate of neutropenia and infections in the daratumumab arms. Regulatory assessment of efficacy and safety results from trials MMY3006, MMY3007, and MMY3008 confirmed a positive benefit‐risk ratio leading to an approval of the extensions of indication. Implications for Practice A set of extensions of indication was recently approved for daratumumab (Darzalex) in the setting of newly diagnosed multiple myeloma in combination with established regimens. Results of the MMY3006, MMY3007, and MMY3008 trials have shown enhanced efficacy and a favorable side effect profile of several daratumumab‐based combinations in patients both ineligible and eligible for transplant, without compromising transplant ability. The combinations of daratumumab with either lenalidomide and low‐dose dexamethasone or bortezomib, melphalan, and prednisone were approved for transplant‐ineligible patients. The combination of daratumumab with bortezomib, thalidomide, and dexamethasone was approved for transplant‐eligible patients. These combinations are expected to improve the survival outlook for patients with multiple myeloma, without an unacceptable risk of increase in adverse events, and updated information on progression‐free survival and overall survival is expected from the above trials. This report outlines the regulatory steps taken for the approval of extensions of indication of daratumumab for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The pivotal clinical data submitted and EMA review of the benefit‐risk assessment are summarized.</description><subject>Daratumumab</subject><subject>European Medicines Agency</subject><subject>Newly diagnosed multiple myeloma</subject><subject>Regulatory Issues: EMA</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoqVw4QcgHwtSyvgjm_iCtNqWD6nbRahI3KxJPOkaOfE2drosv54sWyq4cJoZ-9EzI71Z9pLDGQcQb0PfhDMui0I9yo55oXSuNHx7PPVQybzkhT7KnsX4HWBqpXiaHUkJYlYCHGf9xXLOvtCdoy0LLTvHAdPYjR3W7HQafqKnH69ZGwaW1sSuB8LUUZ_27NyOPrHPmNz0ENkVbf2OnTu86UMky7YurdlyQtzGE1vuyIcOn2dPWvSRXtzXk-zr-4vrxcf8cvXh02J-mTdKgMoboJKwQIVcNjgDri02TalBq0IRl7Yha8FqrLAGIYoZlhaIV4Sztra1lifZu4N3M9YdTXifBvRmM7gOh50J6My_P71bm5twZ0otKwXlJDi9FwzhdqSYTOdiQ95jT2GMRiileSWU2O96c0CbIcQ4UPuwhoPZB2T2AZnfAU3wq78Pe0D_JDIB_ABsnafdf1RmdbVYHaS_ADDsngA</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Michaleas, Sotirios</creator><creator>Penninga, Elisabeth</creator><creator>Hovgaard, Doris</creator><creator>Dalseg, Anne‐Marie</creator><creator>Rosso, Aldana</creator><creator>Sarac, Sinan B.</creator><creator>Jimenez, Jorge Camarero</creator><creator>Fernández, Lucia López‐Anglada</creator><creator>Fernández, Carolina Prieto</creator><creator>Mangas‐SanJuan, Victor</creator><creator>Garcia, Isabel</creator><creator>Payares‐Herrera, Concepcion</creator><creator>Sancho‐López, Aranzazu</creator><creator>Enzmann, Harald</creator><creator>Castro Lopes Silva, Marcia Sofia Sanches</creator><creator>Duarte, Sílvia</creator><creator>Pignatti, Francesco</creator><general>John Wiley &amp; Sons, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8926-2749</orcidid></search><sort><creationdate>202012</creationdate><title>EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma</title><author>Michaleas, Sotirios ; Penninga, Elisabeth ; Hovgaard, Doris ; Dalseg, Anne‐Marie ; Rosso, Aldana ; Sarac, Sinan B. ; Jimenez, Jorge Camarero ; Fernández, Lucia López‐Anglada ; Fernández, Carolina Prieto ; Mangas‐SanJuan, Victor ; Garcia, Isabel ; Payares‐Herrera, Concepcion ; Sancho‐López, Aranzazu ; Enzmann, Harald ; Castro Lopes Silva, Marcia Sofia Sanches ; Duarte, Sílvia ; Pignatti, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Daratumumab</topic><topic>European Medicines Agency</topic><topic>Newly diagnosed multiple myeloma</topic><topic>Regulatory Issues: EMA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michaleas, Sotirios</creatorcontrib><creatorcontrib>Penninga, Elisabeth</creatorcontrib><creatorcontrib>Hovgaard, Doris</creatorcontrib><creatorcontrib>Dalseg, Anne‐Marie</creatorcontrib><creatorcontrib>Rosso, Aldana</creatorcontrib><creatorcontrib>Sarac, Sinan B.</creatorcontrib><creatorcontrib>Jimenez, Jorge Camarero</creatorcontrib><creatorcontrib>Fernández, Lucia López‐Anglada</creatorcontrib><creatorcontrib>Fernández, Carolina Prieto</creatorcontrib><creatorcontrib>Mangas‐SanJuan, Victor</creatorcontrib><creatorcontrib>Garcia, Isabel</creatorcontrib><creatorcontrib>Payares‐Herrera, Concepcion</creatorcontrib><creatorcontrib>Sancho‐López, Aranzazu</creatorcontrib><creatorcontrib>Enzmann, Harald</creatorcontrib><creatorcontrib>Castro Lopes Silva, Marcia Sofia Sanches</creatorcontrib><creatorcontrib>Duarte, Sílvia</creatorcontrib><creatorcontrib>Pignatti, Francesco</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michaleas, Sotirios</au><au>Penninga, Elisabeth</au><au>Hovgaard, Doris</au><au>Dalseg, Anne‐Marie</au><au>Rosso, Aldana</au><au>Sarac, Sinan B.</au><au>Jimenez, Jorge Camarero</au><au>Fernández, Lucia López‐Anglada</au><au>Fernández, Carolina Prieto</au><au>Mangas‐SanJuan, Victor</au><au>Garcia, Isabel</au><au>Payares‐Herrera, Concepcion</au><au>Sancho‐López, Aranzazu</au><au>Enzmann, Harald</au><au>Castro Lopes Silva, Marcia Sofia Sanches</au><au>Duarte, Sílvia</au><au>Pignatti, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2020-12</date><risdate>2020</risdate><volume>25</volume><issue>12</issue><spage>1067</spage><epage>1074</epage><pages>1067-1074</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enhanced efficacy and tolerability in both transplant‐ineligible (MMY3008 and MMY3007) and transplant‐eligible (MMY3006) patients, without compromising transplant ability. Trial MMY3008 showed an improvement in progression‐free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone; the median PFS had not been reached in the daratumumab arm and was 31.9 months in the control arm (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.43–0.73; p &lt; .0001). Trial MMY3007 showed an improvement in PFS when daratumumab was added to bortezomib, melphalan, and prednisone compared with bortezomib, melphalan, and prednisone; PFS had not been reached in the daratumumab arm and was 18.1 months in the control arm (HR, 0.5; 95% CI, 0.38–0.65; p &lt; .0001). In trial MMY3006, daratumumab added to bortezomib, thalidomide, and dexamethasone was compared with bortezomib, thalidomide, and dexamethasone as induction and consolidation treatment prior to autologous stem cell transplant. The stringent complete response rate at day 100 after transplant in the daratumumab group was 29% compared with 20% in the control group (odds ratio, 1.60; 1.21–2.12 95% CI; p = .0010). Overall adverse events were manageable, with an increased rate of neutropenia and infections in the daratumumab arms. Regulatory assessment of efficacy and safety results from trials MMY3006, MMY3007, and MMY3008 confirmed a positive benefit‐risk ratio leading to an approval of the extensions of indication. Implications for Practice A set of extensions of indication was recently approved for daratumumab (Darzalex) in the setting of newly diagnosed multiple myeloma in combination with established regimens. Results of the MMY3006, MMY3007, and MMY3008 trials have shown enhanced efficacy and a favorable side effect profile of several daratumumab‐based combinations in patients both ineligible and eligible for transplant, without compromising transplant ability. The combinations of daratumumab with either lenalidomide and low‐dose dexamethasone or bortezomib, melphalan, and prednisone were approved for transplant‐ineligible patients. The combination of daratumumab with bortezomib, thalidomide, and dexamethasone was approved for transplant‐eligible patients. These combinations are expected to improve the survival outlook for patients with multiple myeloma, without an unacceptable risk of increase in adverse events, and updated information on progression‐free survival and overall survival is expected from the above trials. This report outlines the regulatory steps taken for the approval of extensions of indication of daratumumab for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The pivotal clinical data submitted and EMA review of the benefit‐risk assessment are summarized.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33026700</pmid><doi>10.1002/onco.13554</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8926-2749</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1083-7159
ispartof The oncologist (Dayton, Ohio), 2020-12, Vol.25 (12), p.1067-1074
issn 1083-7159
1549-490X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7938407
source Open Access: Oxford University Press Open Journals; PubMed Central; EZB Electronic Journals Library
subjects Daratumumab
European Medicines Agency
Newly diagnosed multiple myeloma
Regulatory Issues: EMA
title EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A20%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EMA%20Review%20of%20Daratumumab%20(Darzalex)%20for%20the%20Treatment%20of%20Adult%20Patients%20Newly%20Diagnosed%20with%20Multiple%20Myeloma&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Michaleas,%20Sotirios&rft.date=2020-12&rft.volume=25&rft.issue=12&rft.spage=1067&rft.epage=1074&rft.pages=1067-1074&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1002/onco.13554&rft_dat=%3Cproquest_pubme%3E2449182429%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4204-c0e7ea5a4a13ca6019dacc7909454e13dcedd0d9a8ab02256a7d0e18ea6fbdb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2449182429&rft_id=info:pmid/33026700&rfr_iscdi=true